SCHEMBL737068

SCHEMBL737068

COc1cc2oc(-c3ccc(N)cc3)cc(=O)c2c(OC)c1OC

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.78
KMT2A Q03164 2/20 0.78
ALDH1A1 P00352 1/20 0.78
ABCB1 P08183 3/20 0.74
ABCG2 Q9UNQ0 2/20 0.74
TP53 P04637 1/20 0.74
MDM2 Q00987 1/20 0.74
CYP1A1 P04798 3/20 0.69
CYP1B1 Q16678 3/20 0.69
KDM4E B2RXH2 2/20 0.65
POLB P06746 2/20 0.65
MAPT P10636 2/20 0.65
ADORA3 P0DMS8 1/20 0.65
FLT3 P36888 2/20 0.64
CYP1A2 P05177 1/20 0.60
OPRD1 P41143 1/20 0.60
AURKA O14965 1/20 0.59
KDR P35968 1/20 0.59
AURKB Q96GD4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetramethylscutellarein SCHEMBL739115 0.88 MEN1 (1.00) MEN1KMT2AALDH1A1ABCB1ABCG2
SCHEMBL30674796 0.86 MEN1 (0.78) MEN1KMT2AALDH1A1ABCB1ABCG2
SCHEMBL735537 0.86 MAPT (0.85) MEN1KMT2AALDH1A1ABCB1ABCG2
SCHEMBL17258307 0.86 MEN1 (0.78) MEN1KMT2AALDH1A1ABCB1ABCG2
Baicalein Trimethyl Ether SCHEMBL971297 0.86 ABCB1 (0.80) MEN1KMT2AALDH1A1ABCB1ABCG2
Sinensetin SCHEMBL29549544 0.85 ABCB1 (1.00) MEN1KMT2AALDH1A1ABCB1ABCG2
Sinensetin SCHEMBL29700880 0.85 ABCB1 (1.00) MEN1KMT2AALDH1A1ABCB1ABCG2
Sinensetin SCHEMBL621101 0.85 ABCB1 (1.00) MEN1KMT2AALDH1A1ABCB1ABCG2
SCHEMBL1765114 0.84 ABCB1 (1.00) MEN1KMT2AALDH1A1ABCB1ABCG2
SCHEMBL737562 0.84 MEN1 (0.74) MEN1KMT2AALDH1A1ABCB1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138165-B2 Chromones and chromone derivatives and uses thereof JENKEN BIOSCIENCES, INC. (US) 2012-03-20 US disclosed
US-8138165-B2 Chromones and chromone derivatives and uses thereof JENKEN BIOSCIENCES, INC. (US) 2012-03-20 US disclosed
US-8138165-B2 Chromones and chromone derivatives and uses thereof JENKEN BIOSCIENCES, INC. (US) 2012-03-20 US disclosed
EP-1556031-A4 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES INC (US) 2009-03-25 EP disclosed
US-20060142211-A1 Chromones and chromone derivatives and uses thereof TAIWANJ PHARMACEUTICALS CO., LTD. (TW) 2006-06-29 US disclosed
EP-1556031-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF Jenken Bioscience, Inc. (US) 2005-07-27 EP disclosed
WO-2004037193-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES, INC. (US) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142211-A1 Chromones and chromone derivatives and uses thereof PROC, HMGB1, PYCARD MEN1 1195/4885KMT2A 4070/4885ALDH1A1 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.